Proton pump inhibitors reduce duodenal eosinophilia, mast cells and permeability in patients with functional dyspepsia

Despite the growing recognition of duodenal alterations in the pathophysiology of functional dyspepsia (FD), the effect and mechanism of proton pump inhibitors (PPI) or first-line therapy remain unclear. We studied duodenal and systemic alterations in relation to PPI-therapy in FD patients and healthy volunteers (HV).